Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Harnessing AI to optimize the development of new protein manufacturing processes

Industrial yeasts are a powerhouse of protein production, used to manufacture vaccines, biopharmaceuticals, and other useful compounds.

17 Feb 2026

Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Intranasal boosting after prior intramuscular COVID vaccination induced strong mucosal IgA responses in a small human cohort. These antibodies showed markedly enhanced neutralising activity against Omicron variants and evidence of immune memory reprogramming toward mucosal protection.

15 Feb 2026

Survey shows growing public familiarity with RSV vaccines and antibody injections

Amid a surprisingly severe flu season and a Covid-19 resurgence, those highly contagious respiratory illnesses are drawing the largest share of media coverage and public attention.

21 Jan 2026

Researchers discover how Mycoplasma pneumoniae acquires cholesterol from human hosts

A multidisciplinary team has uncovered a key mechanism that allows the human bacterium Mycoplasma pneumoniae-responsible for atypical pneumonia and other respiratory infections-to obtain cholesterol and other essential lipids directly from the human body.

16 Jan 2026

Study provides a new paradigm for managing transplant‑related immune complications

Acute graft-versus-host disease (aGVHD) is one of the most serious complications after allogeneic hematopoietic stem cell transplantation (allo‑HSCT).

16 Jan 2026

Novel antibody shows promise in overcoming resistance to cancer immunotherapy

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the potential to overcome treatment resistance to anti-PD-1 immune checkpoint inhibitors in multiple cancer types.

13 Jan 2026

A single immune protein may help explain why kidney and heart disease often develop together

This review synthesizes clinical, genetic, and mechanistic evidence showing that suPAR and related uPAR fragments are strongly associated with kidney, cardiovascular, and metabolic disease risk. It highlights suPAR as a stable biomarker of innate immune activation with potential pathogenic roles, while underscoring major gaps in assay standardization and therapeutic validation.

6 Jan 2026

RSV prevention: A new era for infant protection

Globally, RSV causes millions of respiratory infections each year and is responsible for a large proportion of hospitalizations and deaths among children under five years, with the highest risk concentrated in infants under six months.

5 Jan 2026

Experimental drug targets early toxic amyloid to slow Alzheimer’s disease

An experimental drug developed at Northwestern University has demonstrated further promise as an early intervention for Alzheimer's disease.

18 Dec 2025

Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children

Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial.

12 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Early-life RSV infection and parental allergy interact to substantially increase childhood asthma risk, supported by population data from more than 1.5 million children and mechanistic mouse experiments. The study shows that viral infection reprograms neonatal immune responses by altering how maternally transferred allergen-specific antibodies are handled, driving long-term allergic airway disease.

8 Dec 2025

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

8 Dec 2025

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with targeted therapies.

5 Dec 2025

Extending the reach of Amperia™: Simplifying his-tagged protein quantification across expression and development workflows

Discover how Abselion’s Amperia™ platform delivers fast, reproducible His-tagged protein quantification with minimal prep, even from crude lysates.

From Abselion 27 Nov 2025

Study elucidates how anti-amyloid antibody therapy lecanemab works in Alzheimer's disease

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline.

25 Nov 2025

Monoclonal Antibody News and Research

Further Reading

Harnessing AI to optimize the development of new protein manufacturing processes

Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus

Chronic inflammation shapes cancer progression and immunotherapy response

Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation

Survey shows growing public familiarity with RSV vaccines and antibody injections

Researchers discover how Mycoplasma pneumoniae acquires cholesterol from human hosts

Study provides a new paradigm for managing transplant‑related immune complications

Novel antibody shows promise in overcoming resistance to cancer immunotherapy

A single immune protein may help explain why kidney and heart disease often develop together

RSV prevention: A new era for infant protection

Experimental drug targets early toxic amyloid to slow Alzheimer’s disease

Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Most T-cell/histocyte-rich large B-cell lymphoma patients can safely receive a less toxic treatment

Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer

Extending the reach of Amperia™: Simplifying his-tagged protein quantification across expression and development workflows

Study elucidates how anti-amyloid antibody therapy lecanemab works in Alzheimer's disease

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®